(Jacob Bruns, Headline USA) As the woke state becomes increasingly desperate to force its religion of transgender onto young children, Big Pharma companies that make puberty blockers are increasingly being allowed to skip safety trials.
Drug manufacturers who make puberty blockers are increasingly refusing to conduct safety tests, presumably for political reasons, the Daily Wire reported.
In particular, manufacturers Endo International plc and AbbVie Inc have declined to conduct safety tests on the puberty blocking drug Lupron.
According to the report, from 2017 to 2021, 17,683 of the 121,882 children ages 6 to 17 who were “diagnosed” with “gender dysphoria” were prescribed life-altering hormones or puberty blockers.
Dr. Brad Miller, division director of pediatric endocrinology at the University of Minnesota Medical School and M Health Masonic Children’s Hospital said that he, along with several colleagues, looked into the matter.
“They would say it would cost a lot of money to get approval,” Miller said of the drug manufacturers’ refusal. “And they were not interested in going there because (transgender treatment) was a political hot potato.”
According to the Food and Drug Administration, the companies lacked any interest in acquiring approval from the agency.
“They said the companies always declined.”
Such a decline indicates that drug manufacturers are just fine raking in big money from the transgender movement. Currently, puberty blocking drugs and other hormones are approved by the FDA only for the treatment of certain conditions relating to children hitting puberty very early, before ages 8 or 9.
The drugs are not approved for treating “gender dysphoria” in adolescent children.
“Hormones released during puberty play a major role in brain development, so when puberty is suppressed, can that result in reduced cognitive function, such as problem solving and decision making?” Reuters asked.
Dr. John Strang, research director of the gender development program at Children’s National Hospital, published a research paper in 2020, concluding that “pubertal suppression may prevent key aspects of development during a sensitive period of brain organization.”
